Furiex Pharmaceuticals major shareholder Buys $1,061,061,270 in Stock (FURX)

Share on StockTwits

Furiex Pharmaceuticals (NASDAQ:FURX) major shareholder Forest Laboratories, Llc acquired 11,169,066 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were purchased at an average price of $95.00 per share, for a total transaction of $1,061,061,270.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Furiex Pharmaceuticals (NASDAQ:FURX) opened at 104.77 on Wednesday. Furiex Pharmaceuticals has a 1-year low of $32.05 and a 1-year high of $121.97. The stock has a 50-day moving average of $104.4 and a 200-day moving average of $84.2. The company’s market cap is $1.132 billion.

Furiex Pharmaceuticals (NASDAQ:FURX) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($1.25) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.63) by $0.62. The company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $10.01 million. During the same quarter last year, the company posted $0.82 earnings per share. Furiex Pharmaceuticals’s revenue was down 83.7% compared to the same quarter last year. Analysts expect that Furiex Pharmaceuticals will post $-2.27 EPS for the current fiscal year.

Furiex Pharmaceuticals, Inc is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas.

Receive News & Ratings for Furiex Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Furiex Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Exxon Mobil Receives Average Recommendation of “Hold” from Brokerages
Exxon Mobil Receives Average Recommendation of “Hold” from Brokerages
CIGNA Receives Consensus Rating of “Buy” from Brokerages
CIGNA Receives Consensus Rating of “Buy” from Brokerages
Constellium NV Receives Consensus Rating of “Hold” from Analysts
Constellium NV Receives Consensus Rating of “Hold” from Analysts
Amazon.com Receives Consensus Rating of “Buy” from Brokerages
Amazon.com Receives Consensus Rating of “Buy” from Brokerages
The Medicines Company Given Average Rating of “Hold” by Analysts
The Medicines Company Given Average Rating of “Hold” by Analysts
Imperial Oil Limited Given Consensus Rating of “Hold” by Brokerages
Imperial Oil Limited Given Consensus Rating of “Hold” by Brokerages


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 Mideast Time.